These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26920590)

  • 21. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
    J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
    Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: results of Korean multicenter angioplasty team (KOMATE) Registry.
    Kim BK; Oh S; Jeon DW; Yang JY; Kim JS; Park S; Choi D; Jang Y; Hong BK; Kwon HM; Lee SW; Goh CW; Kwon K; Ryu SK;
    J Interv Cardiol; 2009 Oct; 22(5):411-9. PubMed ID: 19702679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
    Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
    EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis.
    Ota H; Mahmoudi M; Torguson R; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015; 16(3):151-5. PubMed ID: 25977226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease.
    Wanitschek M; Pfisterer M; Hvelplund A; De Servi S; Bertel O; Jeger R; Rickenbacher P; Iversen A; Jensen JS; Galatius S; Kaiser C; Alber H;
    Int J Cardiol; 2013 Oct; 168(3):2381-8. PubMed ID: 23453439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
    Byrne RA; Kastrati A; Massberg S; Wieczorek A; Laugwitz KL; Hadamitzky M; Schulz S; Pache J; Fusaro M; Hausleiter J; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2011 Sep; 58(13):1325-31. PubMed ID: 21920260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes.
    Applegate RJ; Sacrinty MT; Kutcher MA; Santos RM; Gandhi SK; Little WC
    Circ Cardiovasc Interv; 2009 Feb; 2(1):35-42. PubMed ID: 20031691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes with various drug-eluting or bare metal stents in patients with ST-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials.
    Bangalore S; Amoroso N; Fusaro M; Kumar S; Feit F
    Circ Cardiovasc Interv; 2013 Aug; 6(4):378-90. PubMed ID: 23922145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
    J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
    Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C
    Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR).
    Mieres J; Fernandez-Pereira C; Risau G; Solorzano L; Pauletto R; Rodriguez-Granillo AM; Rubilar B; Stella P; Rodriguez AE
    Cardiovasc Revasc Med; 2012; 13(5):265-71. PubMed ID: 22796496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.